ECSP088509A - Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-asa - Google Patents

Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-asa

Info

Publication number
ECSP088509A
ECSP088509A EC2008008509A ECSP088509A ECSP088509A EC SP088509 A ECSP088509 A EC SP088509A EC 2008008509 A EC2008008509 A EC 2008008509A EC SP088509 A ECSP088509 A EC SP088509A EC SP088509 A ECSP088509 A EC SP088509A
Authority
EC
Ecuador
Prior art keywords
compounds
inhibitors
diseases
formula
treatment
Prior art date
Application number
EC2008008509A
Other languages
English (en)
Inventor
David Barnes
Gary Mark Coppola
Travis Stams
Sidney Wolf Topiol
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37903424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088509(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088509A publication Critical patent/ECSP088509A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Los compuestos de la Fórmula, son inhibidores de las fosfatasas de proteína tirosina (PTPasas), y por lo tanto, se pueden emplear para el tratamiento de las condiciones mediadas por la actividad de la PTPasa. Los compuestos de la presente invención también se pueden emplear como inhibidores de otras enzimas caracterizadas por una región de enlace de fosfotirosina, tal como el dominio SH2. De acuerdo con lo anterior, los compuestos de la Fórmula (I) se pueden emplear para la prevención y/o el tratamiento de resistencia a la insulina asociada con obesidad, intolerancia a la glucosa, diabetes mellitus, hipertensión y enfermedades isquémicas de los vasos sanguíneos grandes y pequeños, condiciones que acompañan a la diabetes tipo 2, incluyendo hiperlipidemia, hipertrigliceridemia, ateroesclerosis, restenosis vascular, síndrome de intestino irritable, pancreatitis, tumores de células adiposas y carcinomas, tales como liposarcoma, dislipidemia, y otros trastornos en donde se indique la resistencia a la insulina. En adición, los compuestos de la presente invención se pueden emplear para tratar y/o prevenir cáncer, osteoporosis, enfermedades neurodegenerativas e infecciosas, y enfermedades que involucren inflamación y al sistema inmune.
EC2008008509A 2005-12-08 2008-06-06 Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-asa ECSP088509A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74849205P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
ECSP088509A true ECSP088509A (es) 2008-07-30

Family

ID=37903424

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008509A ECSP088509A (es) 2005-12-08 2008-06-06 Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-asa

Country Status (23)

Country Link
US (1) US8252820B2 (es)
EP (1) EP1963293A1 (es)
JP (1) JP2009518419A (es)
KR (1) KR20080075218A (es)
CN (1) CN101336235A (es)
AR (1) AR058285A1 (es)
AU (1) AU2006321902B2 (es)
BR (1) BRPI0619567A2 (es)
CA (1) CA2631007A1 (es)
CR (1) CR10047A (es)
EC (1) ECSP088509A (es)
GT (1) GT200800093A (es)
IL (1) IL191711A0 (es)
MA (1) MA30018B1 (es)
NO (1) NO20083030L (es)
NZ (1) NZ568663A (es)
PE (2) PE20100470A1 (es)
RU (1) RU2008127262A (es)
TN (1) TNSN08248A1 (es)
TW (1) TW200800928A (es)
UA (1) UA94921C2 (es)
WO (1) WO2007067612A1 (es)
ZA (1) ZA200804489B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629819A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
CA2630448A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors
CA2647472A1 (en) * 2006-03-31 2007-10-11 Novartis Ag Organic compounds
DE102007015169A1 (de) * 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN103201244B (zh) * 2010-08-26 2015-06-17 阿尔比马尔公司 用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2017078499A2 (ko) * 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
BR112020026086A2 (pt) * 2018-06-21 2021-03-23 Calico Life Sciences Llc inibidores da proteína tirosina fosfatase e métodos de uso destes
US11992012B2 (en) 2018-09-18 2024-05-28 Basf Se Diaminotriazine compounds
IL286373B2 (en) * 2019-03-14 2026-03-01 Calico Life Sciences Llc Protein tyrosine phosphate inhibitor compounds and uses thereof
EP4073242A4 (en) 2019-12-12 2024-01-03 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
CA3162069A1 (en) * 2019-12-18 2021-06-24 Elliot P. Farney Protein tyrosine phosphatase inhibitors and methods of use thereof
EP4077319A1 (en) * 2019-12-20 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase degraders and methods of use thereof
MX2023002953A (es) * 2020-09-11 2023-06-01 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
AU2022212381A1 (en) 2021-01-27 2023-08-10 Basf Se Diaminotriazine compounds
WO2022192598A1 (en) * 2021-03-11 2022-09-15 Kumquat Biosciences Inc. Heterocycles and uses thereof
EP4351558A4 (en) * 2021-06-10 2025-05-07 Ness Therapeutics, Inc. Compounds containing 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
MX2024005656A (es) * 2021-11-11 2024-08-06 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
WO2023086498A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
TW202345805A (zh) * 2022-01-31 2023-12-01 美商必治妥美雅史谷比公司 蛋白酪胺酸磷酸酶抑制劑、其組合物及使用方法
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
PE20250780A1 (es) * 2022-02-02 2025-03-14 Nerio Therapeutics Inc Inhibidores de proteina tirosina fosfatasa y usos de estos
WO2023150535A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
EP4522594A4 (en) * 2022-05-13 2026-04-22 Mondego Bio Lda A Limited Liability Company By Quotas Soc Por Quotas PTPN2 INHIBITORS
CN117658947B (zh) * 2022-09-06 2026-03-06 杭州中美华东制药有限公司 蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物
CN119790052A (zh) * 2022-09-13 2025-04-08 金橘生物科技公司 苯并稠合的n-杂环及其用途
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
JP2025539027A (ja) * 2022-11-09 2025-12-03 ブリストル－マイヤーズ スクイブ カンパニー タンパク質チロシンホスファターゼの阻害剤、組成物、および使用方法
AR131413A1 (es) * 2022-12-21 2025-03-19 Bristol Myers Squibb Co Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
CN118852335A (zh) * 2023-04-28 2024-10-29 中科中山药物创新研究院 噻二唑烷酮衍生物及其制备方法和应用
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
AU2024288616A1 (en) * 2023-07-11 2026-02-12 Shenzhen Zhongge Biological Technology Co., Ltd. Protein tyrosine phosphatase inhibitor, composition comprising same, and medical use thereof
KR20260040037A (ko) * 2023-07-14 2026-03-23 카톨리에케 유니버시테이트 루벤 암 및 대사 질병의 치료를 위한 신규 화합물
WO2025030008A1 (en) * 2023-08-02 2025-02-06 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitor combinations
CN121889379A (zh) * 2023-09-15 2026-04-17 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
CN120004876B (zh) * 2023-11-16 2026-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN119707953A (zh) * 2024-04-19 2025-03-28 中国药科大学 噻二唑烷酮衍生物及其制备方法和应用
US20260008777A1 (en) * 2024-07-08 2026-01-08 Bristol-Myers Squibb Company Inhibitors of protein tyrosine phosphatase, compositions, and methods of use
CN121591722A (zh) * 2024-08-22 2026-03-03 武汉人福创新药物研发中心有限公司 作为蛋白质酪氨酸磷酸酶抑制剂的含双键取代的化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861431B2 (en) * 2001-03-23 2005-03-01 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
KR100868587B1 (ko) * 2002-04-03 2008-11-12 노파르티스 아게 Ｐｔｐａｓｅ 1ｂ 억제제로서의 5-치환된1,1-디옥소-1,2,5-티아졸리딘-3-온 유도체
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
EP1594497B1 (en) * 2002-12-30 2009-05-27 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
UA94724C2 (en) 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
CA2630448A1 (en) 2005-12-08 2007-06-14 Novartis Ag 1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors
CA2629819A1 (en) 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
CA2647472A1 (en) 2006-03-31 2007-10-11 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
IL191711A0 (en) 2008-12-29
ZA200804489B (en) 2009-08-26
AU2006321902B2 (en) 2011-11-10
PE20100470A1 (es) 2010-07-13
TNSN08248A1 (en) 2009-10-30
CA2631007A1 (en) 2007-06-14
KR20080075218A (ko) 2008-08-14
MA30018B1 (fr) 2008-12-01
NZ568663A (en) 2011-07-29
PE20071094A1 (es) 2008-01-07
UA94921C2 (en) 2011-06-25
BRPI0619567A2 (pt) 2011-10-04
US20100035942A1 (en) 2010-02-11
GT200800093A (es) 2010-07-09
EP1963293A1 (en) 2008-09-03
NO20083030L (no) 2008-08-28
WO2007067612A1 (en) 2007-06-14
CN101336235A (zh) 2008-12-31
AU2006321902A1 (en) 2007-06-14
AR058285A1 (es) 2008-01-30
RU2008127262A (ru) 2010-01-20
CR10047A (es) 2008-10-16
TW200800928A (en) 2008-01-01
JP2009518419A (ja) 2009-05-07
US8252820B2 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
ECSP088509A (es) Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-asa
ECSP088506A (es) Derivados de tiadiazol como agentes antidiabeticos
AR066820A1 (es) Compuestos de tiadiazolidin-3 ona
TNSN08247A1 (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2007115058A3 (en) Thiadiazolidinone inhibitors of ptpase
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
BR0308974A (pt) Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
EA201100119A1 (ru) Химические соединения 251
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
WO2008033562A3 (en) Kinase inhibitor compounds
WO2010074588A3 (en) Pharmaceutical compounds
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
WO2008127349A3 (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
IL184678A0 (en) Proteasome inhibitors and methods of using the same
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MY144970A (en) Heterocyclic compounds
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use